{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T14:25:33Z","timestamp":1785075933560,"version":"3.55.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T00:00:00Z","timestamp":1461024000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40272-016-0174-4","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T08:52:32Z","timestamp":1461055952000},"page":"209-219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pediatric Glaucoma: Pharmacotherapeutic Options"],"prefix":"10.1007","volume":"18","author":[{"given":"Monica","family":"Samant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anagha","family":"Medsinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken K.","family":"Nischal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,19]]},"reference":[{"key":"174_CR1","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.2147\/OPTH.S45480","volume":"7","author":"DS Fung","year":"2013","unstructured":"Fung DS, Roensch MA, Kooner KS, Cavanagh HD, Whitson JT. Epidemiology and characteristics of childhood glaucoma: results from the Dallas Glaucoma Registry. Clin Ophthalmol. 2013;7:1739\u201346.","journal-title":"Clin Ophthalmol."},{"issue":"11","key":"174_CR2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0161-6420(84)34141-0","volume":"91","author":"MS Passo","year":"1984","unstructured":"Passo MS, Palmer EA, Van Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology. 1984;91(11):1361\u20133.","journal-title":"Ophthalmology."},{"issue":"6","key":"174_CR3","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1001\/archophthalmol.2010.96","volume":"128","author":"HH Yeung","year":"2010","unstructured":"Yeung HH, Walton DS. Clinical classification of childhood glaucomas. Arch Ophthalmol. 2010;128(6):680\u20134.","journal-title":"Arch Ophthalmol."},{"issue":"5","key":"174_CR4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1091-8531(99)70028-5","volume":"3","author":"RH Taylor","year":"1999","unstructured":"Taylor RH, Ainsworth JR, Evans AR, Levin AV. The epidemiology of pediatric glaucoma: the Toronto experience. J AAPOS. 1999;3(5):308\u201315.","journal-title":"J AAPOS."},{"issue":"9","key":"174_CR5","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1167\/iovs.06-1350","volume":"48","author":"M Papadopoulos","year":"2007","unstructured":"Papadopoulos M, Cable N, Rahi J, Khaw PT, Investigators BIGES. The British Infantile and Childhood Glaucoma (BIG) Eye Study. Invest Ophthalmol Vis Sci. 2007;48(9):4100\u20136.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"3","key":"174_CR6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1600-0420.1995.tb00281.x","volume":"73","author":"ME Turach","year":"1995","unstructured":"Turach ME, Aktan G, Idil A. Medical and surgical aspects of congenital glaucoma. Acta Ophthalmol Scand. 1995;73(3):261\u20133.","journal-title":"Acta Ophthalmol Scand."},{"issue":"1","key":"174_CR7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3928\/01913913-20090101-05","volume":"46","author":"G Coppens","year":"2009","unstructured":"Coppens G, Stalmans I, Zeyen T, Casteels I. The safety and efficacy of glaucoma medication in the pediatric population. J Pediatr Ophthalmol Strabismus. 2009;46(1):12\u20138.","journal-title":"J Pediatr Ophthalmol Strabismus."},{"issue":"2","key":"174_CR8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00148581-200709020-00001","volume":"9","author":"W Moore","year":"2007","unstructured":"Moore W, Nischal KK. Pharmacologic management of glaucoma in childhood. Paediatr Drugs. 2007;9(2):71\u20139.","journal-title":"Paediatr Drugs."},{"issue":"4","key":"174_CR9","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jaapos.2009.04.017","volume":"13","author":"DA Plager","year":"2009","unstructured":"Plager DA, Whitson JT, Netland PA, Vijaya L, Sathyan P, Sood D, et al. Betaxolol hydrochloride ophthalmic suspension 0.25\u00a0% and timolol gel-forming solution 0.25\u00a0% and 0.5\u00a0% in pediatric glaucoma: a randomized clinical trial. J AAPOS. 2009;13(4):384\u201390.","journal-title":"J AAPOS."},{"issue":"3","key":"174_CR10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jaapos.2007.11.004","volume":"12","author":"JT Whitson","year":"2008","unstructured":"Whitson JT, Roarty JD, Vijaya L, Robin AL, Gross RD, Landry TA, et al. Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: a randomized clinical trial. J AAPOS. 2008;12(3):239\u2013246 e3.","journal-title":"J AAPOS."},{"issue":"11","key":"174_CR11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/000992289803701101","volume":"37","author":"DK Wallace","year":"1998","unstructured":"Wallace DK, Steinkuller PG. Ocular medications in children. Clin Pediatr. 1998;37(11):645\u201352.","journal-title":"Clin Pediatr."},{"issue":"1","key":"174_CR12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0002-9394(79)90766-9","volume":"88","author":"RJ Olson","year":"1979","unstructured":"Olson RJ, Bromberg BB, Zimmerman TJ. Apneic spells associated with timolol therapy in a neonate. Am J Ophthalmol. 1979;88(1):120\u20132.","journal-title":"Am J Ophthalmol."},{"issue":"11","key":"174_CR13","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/PEC.0b013e3182aa1384","volume":"29","author":"K Kiryazov","year":"2013","unstructured":"Kiryazov K, Stefova M, Iotova V. Can ophthalmic drops cause central nervous system depression and cardiogenic shock in infants? Pediatr Emerg Care. 2013;29(11):1207\u20139.","journal-title":"Pediatr Emerg Care."},{"issue":"8","key":"174_CR14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/IJG.0b013e31824d1e2f","volume":"22","author":"L Chang","year":"2013","unstructured":"Chang L, Ong EL, Bunce C, Brookes J, Papadopoulos M, Khaw PT. A review of the medical treatment of pediatric glaucomas at Moorfields Eye Hospital. J Glaucoma. 2013;22(8):601\u20137.","journal-title":"J Glaucoma."},{"issue":"10","key":"174_CR15","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/j.ophtha.2011.03.010","volume":"118","author":"T Maeda-Chubachi","year":"2011","unstructured":"Maeda-Chubachi T, Chi-Burris K, Simons BD, Freedman SF, Khaw PT, Wirostko B, et al. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study. Ophthalmology. 2011;118(10):2014\u201321.","journal-title":"Ophthalmology."},{"issue":"3","key":"174_CR16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0161-6420(81)35043-X","volume":"88","author":"CD McMahon","year":"1981","unstructured":"McMahon CD, Hetherington J Jr, Hoskins HD Jr, Shaffer RN. Timolol and pediatric glaucomas. Ophthalmology. 1981;88(3):249\u201352.","journal-title":"Ophthalmology."},{"issue":"6","key":"174_CR17","first-page":"871","volume":"56","author":"E Samochowiec-Donocik","year":"2004","unstructured":"Samochowiec-Donocik E, Koraszewska-Matuszewska B. Influence of beta-adrenergic antagonists on tear secretion in children. Pol J Pharmacol. 2004;56(6):871\u20133.","journal-title":"Pol J Pharmacol."},{"issue":"9","key":"174_CR18","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/archopht.123.9.1177","volume":"123","author":"EZ Ott","year":"2005","unstructured":"Ott EZ, Mills MD, Arango S, Getson AJ, Assaid CA, Adamsons IA. A randomized trial assessing dorzolamide in patients with glaucoma who are younger than 6 years. Arch Ophthalmol. 2005;123(9):1177\u201386.","journal-title":"Arch Ophthalmol."},{"issue":"1","key":"174_CR19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1091-8531(98)90109-4","volume":"2","author":"M Portellos","year":"1998","unstructured":"Portellos M, Buckley EG, Freedman SF. Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma. J AAPOS. 1998;2(1):43\u20137.","journal-title":"J AAPOS."},{"issue":"5","key":"174_CR20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jaapos.2006.07.001","volume":"10","author":"K Sabri","year":"2006","unstructured":"Sabri K, Levin AV. The additive effect of topical dorzolamide and systemic acetazolamide in pediatric glaucoma. J AAPOS. 2006;10(5):464\u20138.","journal-title":"J AAPOS."},{"issue":"1","key":"174_CR21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3129\/i09-198","volume":"45","author":"S Sharan","year":"2010","unstructured":"Sharan S, Dupuis A, Hebert D, Levin AV. The effect of oral acetazolamide on weight gain in children. Can J Ophthalmol. 2010;45(1):41\u20135.","journal-title":"Can J Ophthalmol."},{"issue":"6","key":"174_CR22","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0002-9394(99)00349-9","volume":"128","author":"I Adamsons","year":"1999","unstructured":"Adamsons I. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol. 1999;128(6):774\u20136.","journal-title":"Am J Ophthalmol."},{"issue":"8","key":"174_CR23","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/bjo.87.8.1052","volume":"87","author":"S Morris","year":"2003","unstructured":"Morris S, Geh V, Nischal KK, Sahi S, Ahmed MA. Topical dorzolamide and metabolic acidosis in a neonate. Br J Ophthalmol. 2003;87(8):1052\u20133.","journal-title":"Br J Ophthalmol."},{"issue":"6","key":"174_CR24","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2146\/news120018","volume":"69","author":"K Traynor","year":"2012","unstructured":"Traynor K. FDA approves glaucoma treatment. Am J Health Syst Pharm. 2012;69(6):446.","journal-title":"Am J Health Syst Pharm."},{"issue":"10","key":"174_CR25","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.ophtha.2011.03.039","volume":"118","author":"S Raber","year":"2011","unstructured":"Raber S, Courtney R, Maeda-Chubachi T, Simons BD, Freedman SF, Wirostko B, et al. Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study. Ophthalmology. 2011;118(10):2022\u20137.","journal-title":"Ophthalmology."},{"issue":"6","key":"174_CR26","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jaapos.2009.10.003","volume":"13","author":"AC Black","year":"2009","unstructured":"Black AC, Jones S, Yanovitch TL, Enyedi LB, Stinnett SS, Freedman SF. Latanoprost in pediatric glaucoma\u2013pediatric exposure over a decade. J AAPOS. 2009;13(6):558\u201362.","journal-title":"J AAPOS."},{"issue":"1","key":"174_CR27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/eye.2013.232","volume":"28","author":"MG Uva","year":"2014","unstructured":"Uva MG, Avitabile T, Reibaldi M, Bucolo C, Drago F, Quaranta L, et al. Long-term efficacy of latanoprost in primary congenital glaucoma. Eye. 2014;28(1):53\u20137.","journal-title":"Eye."},{"issue":"8","key":"174_CR28","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/IJG.0b013e31824d4fb9","volume":"22","author":"T Maeda-Chubachi","year":"2013","unstructured":"Maeda-Chubachi T, Chi-Burris K, Simons B, Bremond-Gignac D, Freedman S, Khaw PT, et al. Impact of age, diagnosis, and history of glaucoma surgery on outcomes in pediatric patients treated with latanoprost. J Glaucoma. 2013;22(8):614\u20139.","journal-title":"J Glaucoma."},{"key":"174_CR29","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2147\/OPTH.S59197","volume":"8","author":"JS Myers","year":"2014","unstructured":"Myers JS, Vold S, Zaman F, Williams JM, Hollander DA. Bimatoprost 0.01 % or 0.03 % in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials. Clin Ophthalmol. 2014;8:643\u201352.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"174_CR30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaapos.2008.08.006","volume":"13","author":"TL Yanovitch","year":"2009","unstructured":"Yanovitch TL, Enyedi LB, Schotthoeffer EO, Freedman SF. Travoprost in children: adverse effects and intraocular pressure response. J AAPOS. 2009;13(1):91\u20133.","journal-title":"J AAPOS."},{"issue":"Suppl 1","key":"174_CR31","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.survophthal.2008.08.004","volume":"53","author":"A Alm","year":"2008","unstructured":"Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53(Suppl 1):S93\u2013105.","journal-title":"Surv Ophthalmol."},{"issue":"9","key":"174_CR32","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s003470050326","volume":"95","author":"F Schmidtborn","year":"1998","unstructured":"Schmidtborn F. Systemic side-effects of latanoprost in a child with aniridia and glaucoma. Ophthalmologe. 1998;95(9):633\u20134.","journal-title":"Ophthalmologe."},{"issue":"2","key":"174_CR33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/112067210601600209","volume":"16","author":"U Elgin","year":"2006","unstructured":"Elgin U, Batman A, Berker N, Ilhan B. The comparison of eyelash lengthening effect of latanoprost therapy in adults and children. Eur J Ophthalmol. 2006;16(2):247\u201350.","journal-title":"Eur J Ophthalmol."},{"issue":"11","key":"174_CR34","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bjo.2010.193987","volume":"95","author":"CS Tressler","year":"2011","unstructured":"Tressler CS, Wiseman RL, Dombi TM, Jessen B, Huang K, Kwok KK, et al. Lack of evidence for a link between latanoprost use and malignant melanoma: an analysis of safety databases and a review of the literature. Br J Ophthalmol. 2011;95(11):1490\u20135.","journal-title":"Br J Ophthalmol."},{"issue":"1","key":"174_CR35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10384-010-0904-z","volume":"55","author":"J Park","year":"2011","unstructured":"Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol. 2011;55(1):22\u20137.","journal-title":"Jpn J Ophthalmol."},{"issue":"5","key":"174_CR36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/IOP.0000000000000351","volume":"31","author":"MP Rabinowitz","year":"2015","unstructured":"Rabinowitz MP, Katz LJ, Moster MR, Myers JS, Pro MJ, Spaeth GL, et al. Unilateral prostaglandin-associated periorbitopathy: a syndrome involving upper eyelid retraction distinguishable from the aging sunken eyelid. Ophthal Plast Reconstr Surg. 2015;31(5):373\u20138.","journal-title":"Ophthal Plast Reconstr Surg."},{"issue":"11","key":"174_CR37","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1016\/S0886-3350(03)00470-X","volume":"29","author":"M Packer","year":"2003","unstructured":"Packer M, Fine IH, Hoffman RS. Bilateral nongranulomatous anterior uveitis associated with bimatoprost. J Cataract Refract Surg. 2003;29(11):2242\u20133.","journal-title":"J Cataract Refract Surg."},{"issue":"6","key":"174_CR38","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ajo.2008.08.022","volume":"146","author":"E Fortuna","year":"2008","unstructured":"Fortuna E, Cervantes-Castaneda RA, Bhat P, Doctor P, Foster CS. Flare-up rates with bimatoprost therapy in uveitic glaucoma. Am J Ophthalmol. 2008;146(6):876\u201382.","journal-title":"Am J Ophthalmol."},{"issue":"9","key":"174_CR39","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/bjo.87.9.1091","volume":"87","author":"T Ong","year":"2003","unstructured":"Ong T, Chia A, Nischal KK. Latanoprost in port wine stain related paediatric glaucoma. Br J Ophthalmol. 2003;87(9):1091\u20133.","journal-title":"Br J Ophthalmol."},{"issue":"5","key":"174_CR40","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0021-5155(02)00542-7","volume":"46","author":"H Sakai","year":"2002","unstructured":"Sakai H, Sakima N, Nakamura Y, Nakamura Y, Hayakawa K, Sawaguchi S. Ciliochoroidal effusion induced by topical latanoprost in a patient with sturge-weber syndrome. Jpn J Ophthalmol. 2002;46(5):553\u20135.","journal-title":"Jpn J Ophthalmol."},{"issue":"9","key":"174_CR41","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S0181-5512(08)74730-2","volume":"31","author":"J Gambrelle","year":"2008","unstructured":"Gambrelle J, Denis P, Kocaba V, Grange JD. Uveal effusion induced by topical travoprost in a patient with Sturge-Weber-Krabbe syndrome. J Fr Ophtalmol. 2008;31(9):e19.","journal-title":"J Fr Ophtalmol."},{"issue":"1","key":"174_CR42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/eye.2010.191","volume":"25","author":"PK Addison","year":"2011","unstructured":"Addison PK, Papadopoulos M, Nischal KK, Hykin PG. Serous retinal detachment induced by topical bimatoprost in a patient with Sturge-Weber syndrome. Eye. 2011;25(1):124\u20135.","journal-title":"Eye."},{"issue":"12","key":"174_CR43","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.ophtha.2005.06.035","volume":"112","author":"S Al-Shahwan","year":"2005","unstructured":"Al-Shahwan S, Al-Torbak AA, Turkmani S, Al-Omran M, Al-Jadaan I, Edward DP. Side-effect profile of brimonidine tartrate in children. Ophthalmology. 2005;112(12):2143.","journal-title":"Ophthalmology."},{"issue":"5","key":"174_CR44","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1067\/mpa.2001.117571","volume":"5","author":"LB Enyedi","year":"2001","unstructured":"Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS. 2001;5(5):281\u20134.","journal-title":"J AAPOS."},{"issue":"3","key":"174_CR45","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4321\/S0365-66912006000300007","volume":"81","author":"I Montero-de-Espinosa","year":"2006","unstructured":"Montero-de-Espinosa I, Marquez-de-Aracena R, Morales C. Ocular hypertension in children treated with brimonidine 0.2\u00a0%. A clinical study. Arch Soc Esp Oftalmol. 2006;81(3):155\u20139.","journal-title":"Arch Soc Esp Oftalmol."},{"issue":"1","key":"174_CR46","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/sj.eye.6700520","volume":"18","author":"RJ Bowman","year":"2004","unstructured":"Bowman RJ, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2 % eye drops (Alphagan) in children. Eye. 2004;18(1):24\u20136.","journal-title":"Eye"},{"key":"174_CR47","doi-asserted-by":"crossref","unstructured":"Maris PJ Jr, Mandal AK, Netland PA. Medical therapy of pediatric glaucoma and glaucoma in pregnancy. Ophthalmol Clin N Am. 2005;18(3):461\u20138, vii.","DOI":"10.1016\/j.ohc.2005.05.006"},{"issue":"Pt 6","key":"174_CR48","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/eye.1999.235","volume":"13","author":"G Walters","year":"1999","unstructured":"Walters G, Taylor RH. Severe systemic toxicity caused by brimonidine drops in an infant with presumed juvenile xanthogranuloma. Eye. 1999;13(Pt 6):797\u20138.","journal-title":"Eye."},{"issue":"5","key":"174_CR49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/IJG.0b013e31818624e5","volume":"18","author":"TM Wright","year":"2009","unstructured":"Wright TM, Freedman SF. Exposure to topical apraclonidine in children with glaucoma. J Glaucoma. 2009;18(5):395\u20138.","journal-title":"J Glaucoma."},{"issue":"2","key":"174_CR50","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaapos.2014.11.006","volume":"19","author":"CL Kraus","year":"2015","unstructured":"Kraus CL, Trivedi RH, Wilson ME. Intraocular pressure control with echothiophate iodide in children\u2019s eyes with glaucoma after cataract extraction. J AAPOS. 2015;19(2):116\u2013118 e1.","journal-title":"J AAPOS."},{"issue":"2","key":"174_CR51","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0002-9394(76)90433-5","volume":"82","author":"JT Patten","year":"1976","unstructured":"Patten JT, Cavanagh HD, Allansmith MR. Induced ocular pseudopemphigoid. Am J Ophthalmol. 1976;82(2):272\u20136.","journal-title":"Am J Ophthalmol."},{"issue":"3","key":"174_CR52","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/0003-4819-88-3-362","volume":"88","author":"C Fratto","year":"1978","unstructured":"Fratto C. Provocation of bronchospasm by eye drops. Ann Intern Med. 1978;88(3):362.","journal-title":"Ann Intern Med."},{"issue":"12","key":"174_CR53","first-page":"457","volume":"25","author":"LS Halperin","year":"1993","unstructured":"Halperin LS, Goldman HB. Cystoid macular edema associated with topical echothiophate iodide. Ann Ophthalmol. 1993;25(12):457\u20138.","journal-title":"Ann Ophthalmol."},{"issue":"11","key":"174_CR54","first-page":"1078","volume":"127","author":"LP Kramer","year":"1982","unstructured":"Kramer LP. Eye drops and apnea. Can Med Assoc J. 1982;127(11):1078\u20139.","journal-title":"Can Med Assoc J."},{"issue":"4","key":"174_CR55","first-page":"225","volume":"30","author":"RH Reddy","year":"1982","unstructured":"Reddy RH. Echothiophate iodide: its use in accommodative esotropia (high Ac\/A ratio). Indian J Ophthalmol. 1982;30(4):225.","journal-title":"Indian J Ophthalmol."},{"issue":"3","key":"174_CR56","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3129\/i09-065","volume":"44","author":"JF Bussieres","year":"2009","unstructured":"Bussieres JF, Therrien R, Hamel P, Barret P, Prot-Labarthe S. Retrospective cohort study of 163 pediatric glaucoma patients. Can J Ophthalmol. 2009;44(3):323\u20137.","journal-title":"Can J Ophthalmol."},{"issue":"15","key":"174_CR57","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1517\/14656566.2014.955471","volume":"15","author":"K Lorenz","year":"2014","unstructured":"Lorenz K, Pfeiffer N. Efficacy and safety of tafluprost 0.0015 % and timolol maleate 0.5 % fixed combination in patients with ocular hypertension or open-angle glaucoma. Exp Opin Pharmacother. 2014;15(15):2255\u201362.","journal-title":"Exp Opin Pharmacother"},{"key":"174_CR58","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2147\/OPTH.S44708","volume":"8","author":"K Inoue","year":"2014","unstructured":"Inoue K. Managing adverse effects of glaucoma medications. Clin Ophthalmol. 2014;8:903\u201313.","journal-title":"Clin Ophthalmol."},{"issue":"2","key":"174_CR59","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00055735-199604000-00014","volume":"7","author":"C Baudouin","year":"1996","unstructured":"Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol. 1996;7(2):80\u20136.","journal-title":"Curr Opin Ophthalmol."},{"issue":"7","key":"174_CR60","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1136\/bjophthalmol-2013-304064","volume":"98","author":"I Goldberg","year":"2014","unstructured":"Goldberg I, Gil Pina R, Lanzagorta-Aresti A, Schiffman RM, Liu C, Bejanian M. Bimatoprost 0.03\u00a0%\/timolol 0.5\u00a0% preservative-free ophthalmic solution versus bimatoprost 0.03\u00a0%\/timolol 0.5\u00a0% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. Br J Ophthalmol. 2014;98(7):926\u201331.","journal-title":"Br J Ophthalmol."},{"issue":"1","key":"174_CR61","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1185\/03007995.2014.972500","volume":"31","author":"G Hollo","year":"2015","unstructured":"Hollo G, Ropo A. Intraocular pressure decrease with preservative-free fixed and unfixed combination of tafluprost and timolol in pseudoexfoliative glaucoma. Curr Med Res Opin. 2015;31(1):13\u20136.","journal-title":"Curr Med Res Opin."},{"issue":"6","key":"174_CR62","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1089\/jop.2013.0216","volume":"30","author":"M Iester","year":"2014","unstructured":"Iester M, Telani S, Frezzotti P, Motolese I, Figus M, Fogagnolo P, et al. Ocular surface changes in glaucomatous patients treated with and without preservatives beta-blockers. J Ocul Pharmacol Ther. 2014;30(6):476\u201381.","journal-title":"J Ocul Pharmacol Ther."},{"issue":"12","key":"174_CR63","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s12325-014-0163-3","volume":"31","author":"N Pfeiffer","year":"2014","unstructured":"Pfeiffer N, Traverso CE, Lorenz K, Saarela V, Liinamaa J, Uusitalo H, et al. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015\u00a0% and timolol 0.5\u00a0% versus each of its individual preservative-free components. Adv Ther. 2014;31(12):1228\u201346.","journal-title":"Adv Ther."},{"issue":"7","key":"174_CR64","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1517\/13543784.2011.579901","volume":"20","author":"P Fogagnolo","year":"2011","unstructured":"Fogagnolo P, Rossetti L. Medical treatment of glaucoma: present and future. Expert Opin Invest Drugs. 2011;20(7):947\u201359.","journal-title":"Expert Opin Invest Drugs."},{"issue":"1","key":"174_CR65","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ajo.2007.08.041","volume":"145","author":"NR Rylander","year":"2008","unstructured":"Rylander NR, Vold SD. Cost analysis of glaucoma medications. Am J Ophthalmology. 2008;145(1):106\u201313.","journal-title":"Am J Ophthalmology."},{"issue":"6","key":"174_CR66","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/jop.2014.0170","volume":"31","author":"YI Kim","year":"2015","unstructured":"Kim YI, Kim JH, Lee TY, Lee KW. Efficacy and Safety of Glaucoma Patients\u2019 Switch from a 2\u00a0% Dorzolamide\/0.5\u00a0% Timolol Fixed-Combination Brand-Name Drug to Its Generic Counterpart. J Ocular Pharmacol Ther. 2015;31(6):335\u20139.","journal-title":"J Ocular Pharmacol Ther."},{"issue":"1","key":"174_CR67","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jcjo.2011.12.004","volume":"47","author":"ZN Mammo","year":"2012","unstructured":"Mammo ZN, Flanagan JG, James DF, Trope GE. Generic versus brand-name North American topical glaucoma drops. Can J Ophthalmol. 2012;47(1):55\u201361.","journal-title":"Can J Ophthalmol."},{"issue":"3","key":"174_CR68","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/archopthalmol.2011.1788","volume":"130","author":"RB Freedman","year":"2012","unstructured":"Freedman RB, Jones SK, Lin A, Robin AL, Muir KW. Influence of parental health literacy and dosing responsibility on pediatric glaucoma medication adherence. Arch Ophthalmol. 2012;130(3):306\u201311.","journal-title":"Arch Ophthalmol."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-016-0174-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-016-0174-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-016-0174-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T21:01:35Z","timestamp":1567803695000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-016-0174-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,19]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["174"],"URL":"https:\/\/doi.org\/10.1007\/s40272-016-0174-4","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,19]]}}}